The field of AI ligand pose prediction in the protein binding pockets (aka “AI docking”) witnessed unprecedented development in the last year. Several research groups and companies have presented their …
Receptor.AI, a London-based drug discovery company and NVIDIA Inception member, has successfully integrated NVIDIA BioNeMo cloud APIs with their end-to-end Computer Assisted Drug Discovery (CADD) platform. In doing so, the …
The development of oncology drugs faces significant challenges, including a high failure rate (97%) in clinical trials, due to complex genetic interactions, emerging drug resistance, and limitations in preclinical models. …
We at Receptor.AI are excited to present the next important milestone in the development of our next-generation AI docking model, ArtiDock v1.5. This version contains a carefully tuned architecture and …
The sphere of oncology continues to grapple with the complex nature of brain and central nervous system (CNS) tumors. Data predicts that in 2023, the United States will witness approximately …
Receptor.AI has announced ArtiDock, the best-in-class model for “AI docking," which predicts the binding poses of small molecule ligands in protein binding pockets with unprecedented speed and accuracy.
Recent advances in artificial intelligence (AI) has played a pivotal role in optimizing the small-molecule synthesis, standardization, scalability and CRO-based validation. Despite a dose of skepticism about the growing hype …
What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific or engineering projects. Using a powerful class of ‘multiple’ computer …
STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery and development processes to find drug candidates easier and faster.
Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the timescales, length, complexity and cost of drug discovery. So, what is …
Introduction Glioblastomas (GBM) are devastating brain tumors and rank as one of the most aggressive human cancers with a median overall survival of 15 months. In the U.S., there are …
Arctoris is driven by a relentless pursuit to make drug discovery better. An industry where bringing a single drug to the market costs >$2 billion with success rates <5% must …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.